AbbVie

AbbVie, spun out of Abbott in 2013, is a research-driven pharmaceutical company built around immunology, oncology and neuroscience. For years its fortunes rested on Humira, once the world's best-selling drug, and management has worked hard to replace that lost revenue with newer immunology treatments Skyrizi and Rinvoq, which are now growing quickly. AbbVie has treated the dividend as a priority since the spin-off, raising it every year and combining Abbott's heritage of increases with a comparatively generous yield. The payout is well established and central to the investment case, though investors should weigh the debt load and the ongoing transition beyond Humira. On balance it offers a dependable, growing income backed by a deep drug pipeline.